Acetazolamide Sodium

Familial periodic paralysis, Calorimetry, Indirect, Hypercapnia + 12 more

Treatment

5 FDA approvals

20 Active Studies for Acetazolamide Sodium

What is Acetazolamide Sodium

Acetazolamide

The Generic name of this drug

Treatment Summary

Acetazolamide is a medication sometimes used to help treat seizure disorders, particularly absence seizures. It can also be used as an additional treatment for tonic-clonic, myoclonic, and atonic seizures, especially in women whose seizures are triggered by the menstrual cycle. However, the effects of acetazolamide can quickly wear off due to tolerance. The antiepileptic effect of this drug is thought to be due to its ability to inhibit brain carbonic anhydrase, which increases chloride levels in the brain and increases inhibition.

AcetaZOLAMIDE

is the brand name

Acetazolamide Sodium Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

AcetaZOLAMIDE

Acetazolamide

1978

96

Approved as Treatment by the FDA

Acetazolamide, commonly known as AcetaZOLAMIDE, is approved by the FDA for 5 uses such as Open Angle Glaucoma (OAG) and Other and unspecified effects of high altitude .

Open Angle Glaucoma (OAG)

Other and unspecified effects of high altitude

Altitude Sickness

Open Angle Glaucoma

nonuveitic secondary glaucoma

Effectiveness

How Acetazolamide Sodium Affects Patients

Acetazolamide is a medicine used to reduce the amount of fluid in the body, treat certain types of seizures, and increase urination. It is not a type of antibiotic, but instead belongs to a group of drugs called sulfonamides. It works differently than other medications and has a unique chemical structure and effect on the body.

How Acetazolamide Sodium works in the body

Acetazolamide works in two main ways. First, it reduces the amount of carbon dioxide in the lungs, which increases the amount of oxygen in your blood. Second, it stops a chemical reaction that helps the body absorb hydrogen ions. This affects the way that salt and water are passed out of your body in urine, making you pass more water than usual.

When to interrupt dosage

The measure of Acetazolamide Sodium is contingent upon the identified disorder, including Inflammation, Tonic - clonic seizures and Metabolic Alkalosis. The dosage amount fluctuates according to the method of delivery (e.g. Injection, powder, lyophilized, for solution - Intravenous or Powder, for solution) specified in the table beneath.

Condition

Dosage

Administration

Respiration stimulated

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Urine alkalinization therapy

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Congestive Heart Failure

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Preoperative

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Metabolic Alkalosis

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Open Angle Glaucoma

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Hypercapnia

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

nonuveitic secondary glaucoma

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Swollen feet or ankles

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Familial periodic paralysis

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Calorimetry, Indirect

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Altitude Sickness

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Kidney Calculi

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

salicylate intoxication

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Edema

, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg

, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Warnings

Acetazolamide Sodium Contraindications

Condition

Risk Level

Notes

Acidosis

Do Not Combine

Angle Closure Glaucoma

Do Not Combine

Disease

Do Not Combine

Cirrhosis

Do Not Combine

depressed sodium and/or potassium blood serum levels

Do Not Combine

Glaucoma

Do Not Combine

Sulfonamides

Do Not Combine

Chronic Kidney Disease (CKD)

Do Not Combine

hyperchloremic acidosis

Do Not Combine

Glaucoma

Do Not Combine

Chronic Kidney Disease (CKD)

Do Not Combine

Addison Disease

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Acetazolamide may interact with Pulse Frequency

There are 20 known major drug interactions with Acetazolamide Sodium.

Common Acetazolamide Sodium Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Acetazolamide.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Acetazolamide.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Acetazolamide.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Acetazolamide.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Acetazolamide.

Acetazolamide Sodium Novel Uses: Which Conditions Have a Clinical Trial Featuring Acetazolamide Sodium?

76 active studies are currently being conducted to assess the potential of Acetazolamide Sodium to treat Glaucoma, Preoperative Swelling and other related conditions.

Condition

Clinical Trials

Trial Phases

Hypercapnia

0 Actively Recruiting

Familial periodic paralysis

0 Actively Recruiting

Metabolic Alkalosis

0 Actively Recruiting

Edema

0 Actively Recruiting

Preoperative

0 Actively Recruiting

Calorimetry, Indirect

0 Actively Recruiting

Respiration stimulated

0 Actively Recruiting

Congestive Heart Failure

11 Actively Recruiting

Not Applicable, Phase 1, Phase 2

salicylate intoxication

0 Actively Recruiting

nonuveitic secondary glaucoma

0 Actively Recruiting

Urine alkalinization therapy

0 Actively Recruiting

Altitude Sickness

0 Actively Recruiting

Open Angle Glaucoma

10 Actively Recruiting

Phase 3, Not Applicable, Phase 4

Kidney Calculi

0 Actively Recruiting

Swollen feet or ankles

5 Actively Recruiting

Phase 2, Not Applicable, Phase 4

Patient Q&A Section about acetazolamide sodium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does acetazolamide cause hyponatremia?

"Side effects of acetazolamide can include tingling in the hands and feet, tiredness, drowsiness, depression, decreased sex drive, a bitter or metallic taste in the mouth, nausea, vomiting, stomach cramps, diarrhea, dark stool, increased urination, kidney stones, acidosis (too much acid in the blood), and electrolyte changes (low potassium or sodium levels)."

Answered by AI

Does acetazolamide increase sodium?

"Acetazolamide causes an increase in the loss of sodium and potassium ions into the tubular fluid, which causes urine to become more alkaline. However, the hydrogen ions are retained in the plasma, which causes a mild acidosis. However, the drop in the plasma concentration of hydrogen ions stimulates the activity of carbonic anhydrase, which quickly leads to tolerance to the diuretic action of acetazolamide."

Answered by AI

Does acetazolamide lower sodium?

"Acetazolamide inhibits carbonic anhydrase, causing sodium, bicarbonate, and chloride to be excreted rather than reabsorbed. This also leads to the excretion of excess water."

Answered by AI

What is the use of acetazolamide?

"Acetazolamide is a medication used to treat glaucoma, a condition in which increased pressure in the eye can lead to gradual loss of vision. Acetazolamide works by decreasing the pressure in the eye."

Answered by AI

Clinical Trials for Acetazolamide Sodium

Image of Mumford Professional Centre in Halifax, Canada.

Remote Monitoring for Cardiovascular Disease

18+
All Sexes
Halifax, Canada

The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program. The wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program. The primary objectives of this study are to: 1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not. 2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by: 1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates, 2. Evaluating change in patient bloodwork outcomes, 3. Measuring change is physical ability, 4. Analyzing changes in eating behaviours, and 5. Examining quality of life using validated tools. 3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by: 1. Assessing device adherence 2. Reviewing patient feedback survey, and 3. Determining if clinician team were able to access and interpret data collected throughout the program The secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program. This research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.

Waitlist Available
Has No Placebo

Mumford Professional Centre

Nicholas B Giacomantonio, Medical Doctor

Corsano Health B.V.

Have you considered Acetazolamide Sodium clinical trials?

We made a collection of clinical trials featuring Acetazolamide Sodium, we think they might fit your search criteria.
Go to Trials
Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA

Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.

Waitlist Available
Has No Placebo

Virginia Commonwealth University

Aarti Sarwal

Have you considered Acetazolamide Sodium clinical trials?

We made a collection of clinical trials featuring Acetazolamide Sodium, we think they might fit your search criteria.
Go to Trials

Have you considered Acetazolamide Sodium clinical trials?

We made a collection of clinical trials featuring Acetazolamide Sodium, we think they might fit your search criteria.
Go to Trials